Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Astellas

Status and phase: Completed; Phase 3

Conditions: Hepatitis C

Treatments: Drug: Interferon alfacon-1

Study type: Interventional

Funder types: Industry

Identifiers

NCT00239252

B6431/HCT1

Details and patient eligibility

About

Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hepatitis C patients (high titer, genotype1)

Exclusion criteria

• Patients with autoimmune disorder
• Patients with negative HBs antigen
• Patients with hepatic cirrhosis, hepatic failure and hepatic cancer
• Patients with depression or psychoneurotic disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)